INTRODUCTION
Estimates by radioimmunoassay of the levels of prolactin in samples of human serum or plasma are widely used in the investigation of patients with disorders of fertility, of hypo¬ thalamic or pituitary function and of lactation, and the need for a common stable reference material is acknowledged (Greenwood, 1972) . This paper describes a collaborative study of a preparation of human prolactin given to the World Health Organization and ampouled as the proposed international reference preparation for immunoassay and now established (as authorized by the World Health Organization (1978) ) as the International Reference Preparation of human prolactin for immunoassay (subsequently referred to as the IRP).
AIMS OF THE STUDY
The purpose of the study was to assess the suitability of the IRP to serve as a reference preparation for the estimation of human prolactin in serum or plasma, to compare its potency with that of other standards for human prolactin and, from these comparisons, to define the International Unit (i.u.) for human prolactin for immunoassay in terms of the The International Reference Preparation comprises a batch of about 1400 ampoules coded 75/504. Each ampoule contains human pituitary prolactin, (about 20 µg), human albumin, Lister Elstree batch AR 114/3 (1 mg) and lactose (5 mg) obtained after freeze-drying from 1 ml 0-01 M-ammonium formate solution and then sealed in an atmosphere of nitrogen gas.
Distribution amongst ampoules On receipt at the National Institute for Biological Standards and Controls in February 1975 , the bulk prolactin (Lewis batch 207-38-1) in its original container was placed in a dessicator over phosphorus pentoxide under a vacuum of 0-1 Torr . The mass of prolactin (by difference on the container) was 31-45 mg, the recovered mass was 30-9 mg + 0-55 mg (presumed to be in the washings from the container) and the claimed bulk was 35-3 mg. For filling, the whole bulk was dissolved in 50 ml sterile diluent (0-01 M-ammonium formate, A.R., containing human albumin, Lister Elstree batch 114/3,1 mg/ml, and lactose, 5 mg/ml, pH 6-2). Thereafter handling was under clean but not aseptic conditions and at 4°C. After centrifugation for 15 min at 4°C and 27 000 g, the supernatant fraction was decanted and reserved. The residue was dissolved in 1 ml 0-005 m-HCI, diluted to 50 ml with diluent, centrifuged again (15 min at 4°C and 27 000 g) and the resulting supernatant fraction combined with that obtained after the first centrifugation. The residue was scarcely visible and was discarded. The combined supernatant fractions were further diluted with the diluent (described above) to a concentration of 20-3 µg human prolactin/ml. Equal volumes of this solution were distributed, as one batch, into approximately 1400 ampoules and the ampoule contents were freeze-dried, subjected to secondary desiccation and sealed under nitrogen as described by Campbell (1974 (Finney, 1964 (Fig. 2) .
Ranking order. Figure 2 shows that the agreement on the ordering of the samples with respect to their prolactin content was almost unanimous. Preparation 71/330 was examined in only a few laboratories and hence was not included in this comparison, but the prolactin content was estimated to be very similar to that of 75/523. Without exception, preparation 75/523 was found to contain least prolactin. In all systems, samples of plasma obtained from pregnant women were found to contain a higher concentration of prolactin than any other preparation; the plasma from early pregnancy was found to contain less prolactin (Suh & Frantz, 1974; Von Werder «fe Clemm, 1974; Guyda, 1975 Nicoli, 1967 
